Aminophylline versus furosemide for urine output after adult heart surgery
Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial
This trial will test whether aminophylline or furosemide helps increase urine output and lower the chance of kidney injury in adults having planned cardiac surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 106 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07348510 on ClinicalTrials.gov |
What this trial studies
This interventional comparison enrolls adults aged 18–65 undergoing elective cardiac surgery on cardiopulmonary bypass to compare the diuretic effects of aminophylline and furosemide. Eligible participants have BMI 20–40 and no end‑stage kidney disease, prior dialysis, or prior solid-organ transplant. The protocol administers one of the two diuretics perioperatively and monitors urine output, serum creatinine, and the incidence of cardiac surgery–associated acute kidney injury. The goal is to determine whether aminophylline reduces postoperative AKI frequency or better manages volume compared with a loop diuretic.
Who should consider this trial
Good fit: Adults 18–65 undergoing elective cardiac surgical procedures on cardiopulmonary bypass with BMI between 20 and 40 kg/m2 who do not have end‑stage kidney disease or prior organ transplant.
Not a fit: Patients with stage‑5 chronic kidney disease, those already receiving dialysis, emergency surgery cases, or anyone with sensitivity to aminophylline or furosemide are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the intervention could reduce postoperative acute kidney injury and improve fluid management after cardiac surgery.
How similar studies have performed: Prior analyses suggest loop diuretics have mixed effects on postoperative kidney function while some data indicate aminophylline may lower AKI frequency after cardiac surgery, so this comparison builds on limited and partly promising evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 18-65 years. * Both sexes. * All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.). * Body mass index (BMI) ranged between 20 and 40 kg/m2. Exclusion Criteria: * Sensitivity or contraindication to Aminophylline or furosemide * Stage-5 chronic kidney disease (CKD) \[Glomerular filtration rate (GFR) of less than 15 mL/min\]. * The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease. * Recipients of dialysis before surgery. * Recipients of solid-organ transplantation before surgery. * Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc). * Patient refusal.
Where this trial is running
Cairo
- Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Ahmed M Hassan, MSc
- Email: ahm33hassan@gmail.com
- Phone: 00201033752020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.